Page 40 - BH-2-4

Brain & Heart Neurologic manifestations of IBD

36. Pastorelli L, Dozio E, Pisani LF, et al. Procoagulatory state in doi: 10.1038/s41598-019-50542-0
inflammatory bowel diseases is promoted by impaired intestinal 48. Nunes NS, Chandran P, Sundby M, et al. Therapeutic ultrasound
barrier function. Gastroenterol Res Pract. 2015;2015:189341.
attenuates DSS-induced colitis through the cholinergic anti-
doi: 10.1155/2015/189341 inflammatory pathway. EBioMedicine. 2019;45:495-510.
37. Finnie IA, Shields R, Sutton R, Donnelly R, Morris AI. doi: 10.1016/j.ebiom.2019.06.033
Crohn’s disease and myasthenia gravis: A possible role for
thymectomy. Gut. 1994;35(2):278-279. 49. Elliott RE, Rodgers SD, Bassani L, et al. Vagus nerve
stimulation for children with treatment-resistant epilepsy:
doi: 10.1136/gut.35.2.278 A consecutive series of 141 cases. J Neurosurg Pediatr.
38. Gower-Rousseau C, Reumaux D, Bellard M, Delecourt L, 2011;7(5):491-500.
Ribet M, Colombel JF. Remission of myasthenia gravis after doi: 10.3171/2011.2.PEDS10505
proctocolectomy in a patient with ulcerative colitis. Am J
Gastroenterol. 1993;88(7):1136-1138. 50. Kimura K, Hunter SF, Thollander MS, et al. Concurrence of
inflammatory bowel disease and multiple sclerosis. Mayo
39. Foroozan R, Sambursky R. Ocular myasthenia gravis and Clin Proc. 2000;75(8):802-806.
inflammatory bowel disease: A case report and literature
review. Br J Ophthalmol. 2003;87:1186-1187. doi: 10.4065/75.8.802
doi: 10.1136/bjo.87.9.1186 51. Chen X, Wang S, Mao X, et al. Adverse health effects of
emerging contaminants on inflammatory bowel disease.
40. Gondim FAA, de Oliveira GR, Araújo DF, Souza MHL, Front Public Health. 2023;11:1140786.
Braga LLB, Thomas FP. Two patients with co-morbid
myasthenia gravis in a Brazilian cohort of inflammatory doi: 10.3389/fpubh.2023.1140786
bowel disease. Neuromuscul Disord. 2014;24(11):999-1002. 52. Cotsapas C, Voight BF, Rossin E, et al. Pervasive sharing
doi: 10.1016/j.nmd.2014.06.434 of genetic effects in autoimmune disease. PLoS Genet.
2011;7(8):e1002254.
41. Hayashi K, Kurisu Y, Ohshiba S, et al. Report of a
case of Crohn’s disease associated with hyper-creatine doi: 10.1371/journal.pgen.1002254
phosphokinase-emia. Jpn J Med. 1991;30(5):441-445. 53. Gupta G, Gelfand JM, Lewis JD. Increased risk for
doi: 10.2169/internalmedicine1962.30.441 demyelinating diseases in patients with inflammatory bowel
disease. Gastroenterology. 2005;129(3):819-826.
42. Rakhade SN, Jensen FE. Epileptogenesis in the immature brain:
Emerging mechanisms. Nat Rev Neurol. 2009;5(7):380-391. doi: 10.1053/j.gastro.2005.06.022
doi: 10.1038/nrneurol.2009.80 54. Berer K, Mues M, Koutrolos M, et al. Commensal microbiota
and myelin autoantigen cooperate to trigger autoimmune
43. Musto AE, Walker CP, Petasis NA, Bazan NG. Hippocampal demyelination. Nature. 20116;479(7374):538-541.
neuro-networks and dendritic spine perturbations in
epileptogenesis are attenuated by neuroprotectin D1. PLoS doi: 10.1038/nature10554
One. 2015;10(1):e0116543. 55. Banati M, Csecsei P, Koszegi E, et al. Antibody response against
doi: 10.1371/journal.pone.0116543 gastrointestinal antigens in demyelinating diseases of the
central nervous system. Eur J Neurol. 2013;20(11):1492-1495.
44. Rana A, Musto AE. The role of inflammation in the
development of epilepsy. J Neuroinflammation. 2018;15(1):144. doi: 10.1111/ene.12072
doi: 10.1186/s12974-018-1192-7 56. Nelson SM, Nguyen TM, McDonald JW, MacDonald JK.
Natalizumab for induction of remission in Crohn’s disease.
45. Goyal MK, Singh A, Kumar Gupta Y, Kaur Dhaliwal K, Sood A. Cochrane Database Syst Rev. 2018;8(8):CD006097.
Lenvatinib-induced tumor lysis syndrome in advanced
hepatocellular carcinoma. ACG Case Rep J. 2023;10(9):e01139. doi: 10.1002/14651858.CD006097.pub3
doi: 10.14309/crj.0000000000001139 57. Riazi K, Galic MA, Kuzmiski JB, Ho W, Sharkey KA, Pittman QJ.
Microglial activation and TNFalpha production mediate altered
46. Musto AE, Rosencrans RF, Walker CP, et al. Dysfunctional CNS excitability following peripheral inflammation. Proc Natl
epileptic neuronal circuits and dysmorphic dendritic Acad Sci U S A. 2008;105(44):17151-17156.
spines are mitigated by platelet-activating factor receptor
antagonism. Sci Rep. 2016;6(1):30298. doi: 10.1073/pnas.0806682105
doi: 10.1038/srep30298 58. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction
and maintenance therapy for ulcerative colitis. N Engl J Med.
47. De Caro C, Leo A, Nesci V, et al. Intestinal inflammation
increases convulsant activity and reduces antiepileptic drug 2017;376(18):1723-1736.
efficacy in a mouse model of epilepsy. Sci Rep. 2019;9(1):13983. doi: 10.1056/NEJMoa1606910

Volume 2 Issue 4 (2024) 11 doi: 10.36922/bh.3486